Rachel McMinn, Chief Strategy Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 938 shares at $145.90 ($137K) on 2016-01-04, disclosed to the SEC on 2016-01-05.
Open-market sale of $137k ICPT by Chief Strategy Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $145.90 | 469 | $68K | 50.0% |
| 2 | $145.90 | 469 | $68K | 50.0% |
| Total | $145.90 avg | 938 | $137K | 100% |
| Filing → |
| ICPT | SELL | 2017-10-04 | $17K | — | Filing → |
| ICPT | SELL | 2017-08-02 | $16K | — | Filing → |
| ICPT | SELL | 2017-07-05 | $31K | — | Filing → |